Vieira, R.; Souto, S.B.; Sánchez-López, E.; López Machado, A.; Severino, P.; Jose, S.; Santini, A.; Silva, A.M.; Fortuna, A.; García, M.L.;
et al. Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome—Strategies for In Vivo Administration: Part-II. J. Clin. Med. 2019, 8, 1332.
https://doi.org/10.3390/jcm8091332
AMA Style
Vieira R, Souto SB, Sánchez-López E, López Machado A, Severino P, Jose S, Santini A, Silva AM, Fortuna A, García ML,
et al. Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome—Strategies for In Vivo Administration: Part-II. Journal of Clinical Medicine. 2019; 8(9):1332.
https://doi.org/10.3390/jcm8091332
Chicago/Turabian Style
Vieira, Raquel, Selma B. Souto, Elena Sánchez-López, Ana López Machado, Patricia Severino, Sajan Jose, Antonello Santini, Amelia M. Silva, Ana Fortuna, Maria Luisa García,
and et al. 2019. "Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome—Strategies for In Vivo Administration: Part-II" Journal of Clinical Medicine 8, no. 9: 1332.
https://doi.org/10.3390/jcm8091332
APA Style
Vieira, R., Souto, S. B., Sánchez-López, E., López Machado, A., Severino, P., Jose, S., Santini, A., Silva, A. M., Fortuna, A., García, M. L., & Souto, E. B.
(2019). Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome—Strategies for In Vivo Administration: Part-II. Journal of Clinical Medicine, 8(9), 1332.
https://doi.org/10.3390/jcm8091332